Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
Euretina President Ramin Tadayoni, MD, PhD, Dies at 54
The European Society of Retina Specialists, or Euretina, reported April 20 that its president, retina specialist Ramin Tadayoni, MD, PhD, had died. He was 54. Tadayoni was attending the Brazilian R...
Q1-2024 Ophthalmic Revenue Roundup for Roche, Novartis, and Nicox
Swiss company Roche reported April 24 that Vabysmo sales in Q1-2024 were CHF 847 million ($926.5 million, calculated April 24, 2024), up from CHF 432 million (US $487 million) in Q1-2023. Vabysmo r...
US FDA Rejects Xbrane’s Ranibizumab Biosimilar, Citing Analysis and Manufacturing Issues
Sweden’s Xbrane Biopharma announced April 21 that the US FDA had issued a complete response letter rejecting Xbrane’s ranibizumab biosimilar, branded in Europe as Ximluci. The company said regulato...
New Products Set Upbeat Tone for ASCRS Meeting; Attendance Remains a Concern
New product launches created high surgeon interest at the 2024 meeting of the American Society of Cataract and Refractive Surgery (ASCRS), but the overall mood of the conference was tempered somewh...
Researchers in Georgia Establish Database of Proteins in Aqueous Humor to Advance Vision Research
The National Eye Institute (NEI) announced April 8 that researchers from the Medical College of Georgia at Augusta University had established a database of the proteins found in the eye’s aqueous h...
Second Shake-up May be Underway in the Glaucoma Pharmaceuticals Market
Allergan and Novartis replaced Merck and Pfizer at the top of the glaucoma pharmaceuticals market a decade ago. Now it could be their turn to pass the baton. Allergan, acquired by AbbVie in 2020 an...
Retinal Pharmaceutical Transactions Drive Ophthalmic Deals in First Quarter of 2024
Ophthalmic deals in Q1-2024 reached over $2.1 billion and involved 20 transactions. This compares with $2.0 billion from 17 transactions in Q1-2023 and $570 million from 12 transactions in Q4-2023....
Refractive Atlas Uncovers Pockets of High Opportunity in Des Moines, Syracuse
Refractive procedures in general are driven by the country’s millennial and older Generation Z populations, but the surgery rate is driven by a subset of comparatively educated, affluent, and healt...
Viatris, Ocuphire Announce US Launch of Ryzumvi to Reverse Pupil Dilation
Viatris and Ocuphire Pharma announced April 1 the US launch of Ryzumvi (phentolamine ophthalmic solution) 0.75% for the reversal of pharmacologically induced mydriasis. The US FDA approved Ryzumvi ...
Japanese IOL Maker Hoya Halts Production After Cyberattack
Japanese intraocular lens maker Hoya reported on April 4 that production of several of its products had stopped after a computer system failure, “most likely caused by unauthorized access” to its s...
iDose, Eylea HD, Izervay Get J-Codes for Billing Payers in the US
The Centers for Medicare and Medicaid Services (CMS) has issued J-codes for Glaukos’ iDose, Regeneron’s Eylea HD, and Astellas Pharma’s Izervay. The code for iDose takes effect July 1, 2024, while ...
Lenz Reports Positive Topline Phase III Data in Presbyopia, Plans NDA Submission in Mid-2024
Lenz Therapeutics reported April 3 positive topline results from its Phase III CLARITY trials of LNZ100 and LNZ101 for presbyopia. LNZ100 and LNZ101 are preservative free, single-use, once-daily ey...
Past News Stories
Select US FDA Approvals and Clearances in March 2024
The US FDA granted three clearances through the ophthalmic device division using the 510(k) pathway in March 2024, according to the agency’s database. Cylite received clearance for its HP-OCT. The ...
Ophthalmic Bevacizumab Candidate from Outlook Gains Positive CHMP Opinion
Outlook Therapeutics announced March 22 that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) had issued a positive opinion recommending approval of ONS-5010 (L...
Outlook Leads Latest Ophthalmic Fundraising with $164M in Private Placements
Retinal drug developer Outlook Therapeutics led recent ophthalmic fundraising efforts with two private placements, for proceeds totaling $164 million. Financing announced in the past four weeks tot...
Warburg Pincus Buys Controlling Stake in India’s Appasamy
US-based private equity firm Warburg Pincus and Appasamy Associates announced April 10 that Warburg had bought a controlling stake in the Indian ophthalmic company. Financial details were not discl...
ABVC BioPharma Sells Global Rights to Vitreous Substitute to ForSeeCon Eye for $30 Million Up Front
ABVC BioPharma announced March 26 that it had agreed to license its ophthalmology pipeline, including the vitreous substitute candidate Vitargus, to ForSeeCon Eye. ABVC, of Fremont, California, say...
Study Attempts to Clarify Best Fit for Vyzulta
Constance Okeke, MD, is helping to clear the confusion that can come from having multiple choices. “There are so many medicines coming into glaucoma that it can be difficult for a clinician to know...
US FDA Backs Call to Eliminate Interchangeability Designation for Biosimilars
A US FDA official has expressed support for measures before Congress to remove the interchangeability designation for biosimilars, claiming that the two-tier system is only causing confusion. It ca...
ASCRS Marks 50 Years with Look Back at Cataract Surgery in 1974
The ASCRS commemorated its 50th anniversary at its 2024 annual meeting by re-creating an ophthalmologist’s office and surgery suite from the 1970s in the exhibit hall. The display served as a remin...
J&J Vision Launches Tecnis Odyssey PC-IOL at 2024 ASCRS Meeting
Johnson & Johnson Vision launched and touted the Tecnis Odyssey presbyopia-correcting IOL at a number of venues at the 2024 ASCRS meeting. Blake Williamson, MD, and Priya Matthews, MD, described J&...
RxSight Launches the LAL+ IOL with Large ASCRS Program
RxSight continued to build momentum for its post-op adjustable IOL with a big presence at the 2024 ASCRS meeting, including an Eyecelerator presentation on the new LAL+ and 14 speaker sessions at t...
Rayner and Carl Zeiss Meditec Display Recently Acquired Phaco Machines
The US ultrasonic cataract machine market has been dominated by Alcon, Bausch + Lomb, and Johnson & Johnson for more than a decade, so it’s unusual to learn of a new phaco machine being launched by...
Slade’s Steinert Lecture Bolsters Value of Refractive Lens Exchange
Stephen Slade, MD, promoted the value of refractive lens exchange (RLE) during the Steinert Lecture at the 2024 ASCRS meeting’s Refractive Subspecialty Day. RLE is an elective procedure that remove...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.